Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability Comparison of Flarex to Lotemax SM
NCT07588074Phase 4Completed
- Sponsor
- Harrow
- Start
- May 2021
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of fluorometholone acetate in ocular inflammation, allergic conjunctivitis (AC), dry eye disease (DED), postoperative complications, sponsored by Harrow. Started May 2021; status: completed.
02
Drugs
fluorometholone acetate
03
Conditions
ocular inflammationallergic conjunctivitis (AC)dry eye disease (DED)postoperative complications
Beyond the preview
Go deeper on NCT07588074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588074.